At a May conference in Washington D.C., a 23-year-old panelist shared a deeply personal account of a distressing condition she attributed to her antidepressant use: a complete loss of sexual and emotional function. She described experiencing genital numbness and an inability to feel love for her mother, connect with friends, or find pleasure in music.
This condition, known as post-SSRI sexual dysfunction (PSSD), was detailed by Lauren Friedman at the Make America Healthy Again Institute’s Mental Health and Overmedicalization Summit. Friedman stated, “Before this, I was a super emotional, empathetic, loving, caring, Sylvia Plath-reading and -resonating girl. The day I woke up with this injury, I quite literally felt my soul leave my body.”
Video of Friedman’s testimony gained significant traction on social media, sparking discussions and concern across various platforms, including podcasts and news articles. Her story continued to attract millions of views into July.
While sexual side effects are known potential side effects of SSRIs – a class of antidepressants that elevate serotonin levels in the brain and are commonly prescribed for anxiety, depression, and OCD – Friedman’s experience highlighted persistent physical and neurological symptoms that continued long after discontinuing the medication.
The term PSSD emerged in online communities in the early 2000s and was first documented in scientific literature in 2006. While some research suggests a link with other antidepressant classes like SNRIs and TCAs, comprehensive research remains limited. The condition is not formally recognized in major diagnostic manuals like the DSM or ICD.
Friedman’s widely shared experience comes at a time when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. has expressed a desire to reduce antidepressant use in the nation, citing concerns about societal issues, though scientific data does not support a direct link between antidepressants and mass violence. Current data indicates that approximately 16.6% of U.S. adults and 3.6% of children used antidepressants in recent years.
Evidence regarding PSSD primarily stems from individual reports rather than large-scale studies, making it challenging to ascertain its prevalence and causes.
### Limited Research Prompts Calls for Further Investigation
In 2022, a group of researchers, including psychiatrist Dr. David Healy, proposed diagnostic criteria for PSSD. These criteria included symptoms such as a loss of genital sensation, reduced sexual desire, erectile dysfunction, and an inability to achieve orgasm, lasting for at least three months after discontinuing SSRIs. The severity of these cases can vary, with some individuals experiencing spontaneous resolution.
The PSSD Network, an advocacy group established in 2022, is actively campaigning for more research into the condition. They note that some individuals also report non-sexual symptoms, such as emotional numbness, disinterest, and a sense of detachment from others, mirroring some of Friedman’s described experiences. While these symptoms can overlap with depression and anxiety, persistent genital numbness is considered a distinguishing factor.
Dr. Jonathan Alpert, a psychiatrist and professor at Albert Einstein College of Medicine, points out that many existing PSSD studies have not adequately controlled for underlying conditions like depression or anxiety for which antidepressants were initially prescribed. He describes the current body of research as “small and of variable quality.” Dr. Michael Ziffra, a psychiatrist and associate professor at Northwestern University, notes that while a correlation between these medications and PSSD symptoms may exist, the evidence for causation is weaker, and the biological mechanisms are not yet understood.
### Prevalence Remains Unknown
The scarcity of research on PSSD means its actual prevalence is unclear. Dr. Ziffra states that current understanding suggests it is an “uncommon experience for the vast majority of patients taking SSRIs,” with sexual side effects typically resolving within weeks or months of discontinuing the medication in his clinical experience.
The PSSD Network has highlighted two studies offering potential insights. One study examining men’s medical records in Israel indicated a higher prescription rate for erectile dysfunction medications among those who had used serotonin-boosting antidepressants compared to non-users. However, within the group that took antidepressants, only a small fraction met the specific criteria for PSSD.
Another study, based on an online survey of LGBTQ+ youth, reported a higher percentage of individuals experiencing persistent genital numbness after antidepressant use compared to users of other psychiatric medications. However, this survey also noted potential confounding factors, such as the influence of gender-affirming hormone treatment, sedatives, or severe depression on reported symptoms.
Dr. Alpert reiterates that while online communities suggest a high prevalence, other research approaches generally indicate a very low prevalence, and it remains difficult to definitively separate these side effects from the underlying conditions. Dr. Healy believes that the difficulty in tracking PSSD prevalence is due to individuals’ reluctance to discuss their symptoms and the lack of sufficient follow-up on sexual side effects in clinical trials after medication discontinuation. There is a consensus that more research is urgently needed.
### Acknowledgment of Risk by Health Agencies
In response to advocacy and emerging data, some international regulatory bodies, including the European Medicines Agency, have updated drug information for SSRIs and SNRIs to include warnings about the possibility of persistent sexual side effects. The DSM-5 also includes a disclaimer within its section on substance/medication-induced sexual dysfunction, stating that “in some cases, serotonin reuptake inhibitor–induced sexual dysfunction may persist after the agent is discontinued.”
In 2018, a citizen’s petition was submitted to the U.S. Food and Drug Administration requesting additional warnings on antidepressant labels.
Dr. Ziffra notes that while the medical community agrees more research is necessary to “better characterize this phenomenon,” there is not yet a consensus on the strength of the causal link or the underlying biological mechanisms. Dr. Alpert emphasizes that patient reports are valuable for understanding treatment risks and benefits, even before conclusive research is available, and that reports of persistent sexual side effects are being taken seriously.
While future research may establish a stronger link between SSRIs and these effects, Dr. Ziffra advises against drastic measures to discontinue antidepressants based solely on these concerns, recommending that individuals with worries discuss them with their doctor.
Reference